Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Contineum Therapeutics Inc’s current trading price is -54.74% away from its 52-week high, while its distance from the 52-week low is 177.61%. The stock’s price range during this period has varied between $3.35 and $20.55. The company, active in the Healthcare sector, saw a trading volume of around 0.53 million for the day, considerably higher average daily volume of 0.22 million observed over the last three months.
Contineum Therapeutics Inc (CTNM) currently has a stock price of $9.3. The stock saw a sharp increase in the last trading session, hitting a high of $29.0 after opening at $9.3. The lowest recorded price for the day was $16.0 before it closed at $8.1.
The market performance of Contineum Therapeutics Inc has been somewhat unstable. Over the past year, the company’s stock achieved a high of $20.55 on 08/26/24, with the lowest value for the same timeframe being $3.35, recorded on 05/29/25.
How Financial Performance Impacts Market Capitalization
Contineum Therapeutics Inc (CTNM) has experienced a quarterly rise of 112.81% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 260.79M and boasts a workforce of 41 employees.
Decoding Analysts’ Ratings for Contineum Therapeutics Inc
As of right now, 4 analysts are rating Contineum Therapeutics Inc as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 4.82, with a change in price of +2.02. Similarly, Contineum Therapeutics Inc recorded 174,552 in trading volume during the last 100 days, posting a change of +27.75%.
How CTNM’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for CTNM stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.02.
CTNM Stock Stochastic Average
As of today, the raw stochastic average of Contineum Therapeutics Inc over the last 50 days is at 96.95%. This shows a increasee from the raw stochastic average of the previous 20 days, which was recorded at 95.92%. Further, the company’s Stochastic %K and %D values for the last 20 days were 91.54% and 93.50%, respectively.
CTNM Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Year to date metric has recorded a loss of -49.97%.However, over the last six months, we can see a weaker performance of 26.36%. Over the last 30 days, the price of CTNM has fallen by 64.60%. And in the last five days, it has surged by 37.78%.
